Overview

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Status:
Completed

Trial end date:
2019-03-20

Target enrollment:

Participant gender:

Summary

The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P. aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa colonization.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborators:

Erasmus Medical Center
Erasmus Medical Centrum Rotterdam, NL
Fundació Clínic per a la Recerca Biomèdica, ES
Fundacion Clinic per a la Recerca Biomedica
Papworth Hospital Cambridge, UK
Queen's University Belfast, UK
Royal Brompton Hospital Trust, UK
University Hospital Antwerp, BE
University of Dundee
University of Dundee, UK
University of Edinburgh
University of Edinburgh, UK
University of Milan, IT

Treatments:

Tobramycin